Fighting childhood cancer, one cup at a time.
In 2017, the FDA approved CAR T cell immunotherapy as a treatment for children with B-cell acute lymphoblastic leukemia (ALL) who have relapsed or didn’t respond to standard regimens.
CAR T cell immunotherapy makes use of a patient’s own immune cells, which are genetically modified to seek out and kill cancer cells.
But before CAR T immunotherapy was approved by the FDA, it was Stephan Grupp, MD/PhD from Children’s Hospital of Philadelphia (CHOP) who delivered the... Read More
As the Alex’s Lemonade Stand Foundation (ALSF) Director of Science, I work to evaluate our funded research projects to track progress and find gaps in funding so that we can direct more research dollars to the largest areas of need, and to understand the challenges researchers face on a day-to-day basis. I am so excited about where the field of childhood cancer research is going, and I look forward to sharing breakthroughs more often.
Each quarter, I will highlight a few research projects that I think are both interesting and impactful. ALSF has funded more than 1,000 research... Read More
As researchers continue to move closer to cures for all children, there are still types of childhood cancer that continue to be incurable. In the spirit of Alex’s legacy, Alex’s Lemonade Stand Foundation (ALSF) has committed $18.5 million, the single, largest funding commitment from ASLF to date, to four game-changing, collaborative projects at 15 institutions in the United States and Europe. Funded through the Crazy 8 Initiative, these projects are taking on the most deadly childhood cancers with one singular focus:... Read More
